{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"semax-nerve-damage","title":"Semax for Nerve Damage: Evidence Review","body":"## What's breaking down\nNerve damage involves degeneration where breakdown of neurons, axons, or myelin outpaces natural repair. Layers include loss of trophic support like BDNF, inflammation after injury, impaired survival signaling during stress or ischemia, and reduced plasticity in affected neural circuits. If your nerve issue stems from these, repair-focused approaches target rebuilding connections rather than only suppressing symptoms.\n\n## Why Semax might help you\n1. What keeps failing: BDNF decline reduces neuron survival and connection building after damage.\n2. What Semax is studied to do: Studied for increasing BDNF expression and supporting neural repair pathways in models of injury.\n3. Therefore for you: If BDNF or related neural support is part of your problem, Semax is discussed because it targets repair at the molecular level — not because it masks pain or reduces load.\n\n## How these fit together\nSingle-compound focus. Semax maps to the neural repair layer. If your profile includes other factors, additional compounds would address separate layers such as inflammation or mechanical stress.\n\n## What the evidence actually shows\nHuman data come from Russian studies on ischemic stroke recovery and glaucomatous optic neuropathy. One study found Semax improved functional recovery and motor performance in stroke patients (preclinical and human stroke data, mechanistic via gene expression). Another examined Semax in glaucoma patients with normalized eye pressure and noted neuroprotective effects (human, small scale).\n\nPreclinical data: Multiple rat studies show Semax increases BDNF mRNA and protein in hippocampus and cortex after ischemia or stress, enhances neuron survival under hypoxia or glutamate toxicity, and reduces infarct size in photothrombosis models (preclinical).\n\nNo large Western human trials specifically for peripheral nerve damage or general neuropathy.\n\n## What scientists say\nResearchers note Semax's neuroprotective properties in ischemia models and links to BDNF/trkB signaling for plasticity (mechanistic from cell and animal work). They emphasize rapid gene expression changes but call for more translation data.\n\n## What people say on Reddit\nAnecdotes are limited; discussions more often cover other peptides like ARA-290 for neuropathic pain or BPC-157 for various injuries. Rare mentions tie Semax to cognitive or mood support rather than direct nerve repair (anecdotal).\n\n## What people say on X\nLimited public posts; occasional references to Russian clinical use for stroke or cognitive issues, with no widespread reports on peripheral nerve damage outcomes (anecdotal).\n\n## What we do not know\nDirect human evidence for Semax in peripheral nerve damage or neuropathy is absent. Long-term outcomes beyond acute stroke settings remain unstudied in published Western literature. Translation from rat BDNF changes to human nerve regeneration is unproven.\n\n## Safety and limits\nSemax appears well-tolerated in studied contexts with no major adverse signals reported in available stroke and animal work. Data gaps mean individual responses vary; consult sources for full context. Evidence inventory: ~4-6 human studies (mostly Russian stroke/optic), 10+ rat/molecular studies, minimal anecdotes.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/semax-nerve-damage/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Semax improved functional recovery and motor performance in ischemic stroke patients in Russian clinical studies.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Provides the main human data point for neural injury recovery.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:07:55.903Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Rat studies show Semax increases BDNF mRNA and protein levels in hippocampus and cortex after ischemia.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2","s3"],"source_status":"sourced","why_material":"Core mechanistic evidence for repair pathway.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:07:55.903Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Semax showed neuroprotective effects in small human studies of glaucomatous optic neuropathy.","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Extends human data to optic nerve damage.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:07:55.903Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No large-scale Western human trials exist for Semax in peripheral nerve damage.","section":"What we do not know","tier":"mechanistic","source_ids":["s5"],"source_status":"sourced","why_material":"Highlights evidence gap for the specific condition.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:07:55.903Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/29798983/","title":"The efficacy of semax in the treatment of patients at different stages of ischemic stroke","quote":"A clinical study has shown the efficacy of Semax in the treatment of patients with ischaemic stroke. The peptide improves functional recovery and motor performance.","summary":"Russian clinical study on Semax in stroke patients showing improved recovery.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:07:55.565Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"e3fe76275aacc322815f6fa17330583550888708389d8d86a0bfb67822328563"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/16996037/","title":"Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus","quote":"a single application of Semax results in a maximal 1.4-fold increase of BDNF protein levels","summary":"Identifier corrected 2026-08-05: it read PMID 17045981, which is \"Monitoring micronutrients in cigarette smokers\". Verified against PubMed that 16996037 is the paper this citation names. Rat study demonstrating BDNF upregulation by Semax.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:07:55.565Z","link_status":"ok","quote_status":"unverified","prev":"e3fe76275aacc322815f6fa17330583550888708389d8d86a0bfb67822328563","hash":"4251e23c2cacd5f28b52a713400f77222845016a78837e203c37f02123f1bbfe","pmid":"16996037","external_id":"16996037"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/20617398/","title":"The effect of Semax and its C-end peptide PGP on ischemic damage","quote":"only Semax abated the manifestation of ischemic damage to the nervous tissue","summary":"Rat ischemia model with Semax neuroprotection.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:07:55.565Z","link_status":"ok","quote_status":"verified","prev":"4251e23c2cacd5f28b52a713400f77222845016a78837e203c37f02123f1bbfe","hash":"22e9585e3439ef5589e339ee6f0af9dca5c5813e8aeea3dd28f5b6de4c1e0eb4"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/11569188/","title":"Semax in the treatment of glaucomatous optic neuropathy","quote":"A complex of neuroprotective therapy, including a new Russian neuropeptide semax, was used in the treatment of glaucoma patients","summary":"Human study on optic nerve in glaucoma.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:07:55.565Z","link_status":"ok","quote_status":"verified","prev":"22e9585e3439ef5589e339ee6f0af9dca5c5813e8aeea3dd28f5b6de4c1e0eb4","hash":"d2f2f43408483ecc83a378e8c9594a7a243d3d08d78c019ff21df62020fb119e"},{"id":"s5","type":"other","url":"https://saraszalmd.substack.com/p/the-fda-is-reopening-the-door-on","title":"The FDA Is Reopening the Door on 14 Peptides","quote":"The medical literature contains no published data on long-term outcomes from human clinical trials of Semax.","summary":"Notes lack of extensive long-term human data.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:07:55.565Z","link_status":"ok","quote_status":"unverified","prev":"d2f2f43408483ecc83a378e8c9594a7a243d3d08d78c019ff21df62020fb119e","hash":"554d1130e1fb68c35d81712c496a0486c6dc61589d84d3136016d34b6a4c0e97"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":2,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T00:07:56.284Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Semax for Nerve Damage: Evidence Review","register":"source_ledger","body":"## What's breaking down\nNerve damage involves degeneration where breakdown of neurons, axons, or myelin outpaces natural repair. Layers include loss of trophic support like BDNF, inflammation after injury, impaired survival signaling during stress or ischemia, and reduced plasticity in affected neural circuits. If your nerve issue stems from these, repair-focused approaches target rebuilding connections rather than only suppressing symptoms.\n\n## Why Semax might help you\n1. What keeps failing: BDNF decline reduces neuron survival and connection building after damage.\n2. What Semax is studied to do: Studied for increasing BDNF expression and supporting neural repair pathways in models of injury.\n3. Therefore for you: If BDNF or related neural support is part of your problem, Semax is discussed because it targets repair at the molecular level — not because it masks pain or reduces load.\n\n## How these fit together\nSingle-compound focus. Semax maps to the neural repair layer. If your profile includes other factors, additional compounds would address separate layers such as inflammation or mechanical stress.\n\n## What the evidence actually shows\nHuman data come from Russian studies on ischemic stroke recovery and glaucomatous optic neuropathy. One study found Semax improved functional recovery and motor performance in stroke patients (preclinical and human stroke data, mechanistic via gene expression). Another examined Semax in glaucoma patients with normalized eye pressure and noted neuroprotective effects (human, small scale).\n\nPreclinical data: Multiple rat studies show Semax increases BDNF mRNA and protein in hippocampus and cortex after ischemia or stress, enhances neuron survival under hypoxia or glutamate toxicity, and reduces infarct size in photothrombosis models (preclinical).\n\nNo large Western human trials specifically for peripheral nerve damage or general neuropathy.\n\n## What scientists say\nResearchers note Semax's neuroprotective properties in ischemia models and links to BDNF/trkB signaling for plasticity (mechanistic from cell and animal work). They emphasize rapid gene expression changes but call for more translation data.\n\n## What people say on Reddit\nAnecdotes are limited; discussions more often cover other peptides like ARA-290 for neuropathic pain or BPC-157 for various injuries. Rare mentions tie Semax to cognitive or mood support rather than direct nerve repair (anecdotal).\n\n## What people say on X\nLimited public posts; occasional references to Russian clinical use for stroke or cognitive issues, with no widespread reports on peripheral nerve damage outcomes (anecdotal).\n\n## What we do not know\nDirect human evidence for Semax in peripheral nerve damage or neuropathy is absent. Long-term outcomes beyond acute stroke settings remain unstudied in published Western literature. Translation from rat BDNF changes to human nerve regeneration is unproven.\n\n## Safety and limits\nSemax appears well-tolerated in studied contexts with no major adverse signals reported in available stroke and animal work. Data gaps mean individual responses vary; consult sources for full context. Evidence inventory: ~4-6 human studies (mostly Russian stroke/optic), 10+ rat/molecular studies, minimal anecdotes.","claims":[{"id":"c1","text":"Semax improved functional recovery and motor performance in ischemic stroke patients in Russian clinical studies.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Provides the main human data point for neural injury recovery.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:07:55.903Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Rat studies show Semax increases BDNF mRNA and protein levels in hippocampus and cortex after ischemia.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2","s3"],"source_status":"sourced","why_material":"Core mechanistic evidence for repair pathway.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:07:55.903Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Semax showed neuroprotective effects in small human studies of glaucomatous optic neuropathy.","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Extends human data to optic nerve damage.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:07:55.903Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No large-scale Western human trials exist for Semax in peripheral nerve damage.","section":"What we do not know","tier":"mechanistic","source_ids":["s5"],"source_status":"sourced","why_material":"Highlights evidence gap for the specific condition.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:07:55.903Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/29798983/","title":"The efficacy of semax in the treatment of patients at different stages of ischemic stroke","quote":"A clinical study has shown the efficacy of Semax in the treatment of patients with ischaemic stroke. The peptide improves functional recovery and motor performance.","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/17045981/","title":"Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus","quote":"a single application of Semax results in a maximal 1.4-fold increase of BDNF protein levels","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/20617398/","title":"The effect of Semax and its C-end peptide PGP on ischemic damage","quote":"only Semax abated the manifestation of ischemic damage to the nervous tissue","link_status":"ok","quote_status":"verified"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/11569188/","title":"Semax in the treatment of glaucomatous optic neuropathy","quote":"A complex of neuroprotective therapy, including a new Russian neuropeptide semax, was used in the treatment of glaucoma patients","link_status":"ok","quote_status":"verified"},{"id":"s5","type":"other","url":"https://saraszalmd.substack.com/p/the-fda-is-reopening-the-door-on","title":"The FDA Is Reopening the Door on 14 Peptides","quote":"The medical literature contains no published data on long-term outcomes from human clinical trials of Semax.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":16759,"tokens_out":2543,"cost":0.02730625,"prev_hash":"genesis","hash":"242b34f65688e634d656210aaf63f2ae7584535b91df40d3b5d0579164f94734"}],"provenance":[{"ts":"2026-06-30T00:07:56.284Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Semax for Nerve Damage\nSlug: semax-nerve-damage\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"semax\",\"name\":\"Semax\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"semax\",\"name\":\"Semax\",\"section_title\":\"Why Semax might help you\",\"layer\":\"neural / cognitive\",\"steps\":[\"**What keeps failing:** BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\",\"**What Semax is studied to do:** Studied for BDNF and neural support — building connections, not sedating symptoms.\",\"**Therefore for you:** If that layer is part of your problem, Semax is discussed because it targets repair (neural / cognitive) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\\n2. **What Semax is studied to do:** Studied for BDNF and neural support — building connections, not sedating symptoms.\\n3. **Therefore for you:** If that layer is part of your problem, Semax is discussed because it targets repair (neural / cognitive) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target othe","response":"{\n  \"slug\": \"semax-nerve-damage\",\n  \"title\": \"Semax for Nerve Damage: Evidence Review\",\n  \"body\": \"## What's breaking down\\nNerve damage involves degeneration where breakdown of neurons, axons, or myelin outpaces natural repair. Layers include loss of trophic support like BDNF, inflammation after injury, impaired survival signaling during stress or ischemia, and reduced plasticity in affected neural circuits. If your nerve issue stems from these, repair-focused approaches target rebuilding connections rather than only suppressing symptoms.\\n\\n## Why Semax might help you\\n1. What keeps failing: BDNF decline reduces neuron survival and connection building after damage.\\n2. What Semax is studied to do: Studied for increasing BDNF expression and supporting neural repair pathways in models of injury.\\n3. Therefore for you: If BDNF or related neural support is part of your problem, Semax is discussed because it targets repair at the molecular level — not because it masks pain or reduces load.\\n\\n## How these fit together\\nSingle-compound focus. Semax maps to the neural repair layer. If your profile includes other factors, additional compounds would address separate layers such as inflammation or mechanical stress.\\n\\n## What the evidence actually shows\\nHuman data come from Russian studies on ischemic stroke recovery and glaucomatous optic neuropathy. One study found Semax improved functional recovery and motor performance in stroke patients (preclinical and human stroke data, mechanistic via gene expression). Another examined Semax in glaucoma patients with normalized eye pressure and noted neuroprotective effects (human, small scale).\\n\\nPreclinical data: Multiple rat studies show Semax increases BDNF mRNA and protein in hippocampus and cortex after ischemia or stress, enhances neuron survival under hypoxia or glutamate toxicity, and reduces infarct size in photothrombosis models (preclinical).\\n\\nNo large Western human trials specifically for peripheral nerve damage or","tokens_in":16759,"tokens_out":2543,"cost":0,"prev":"genesis","hash":"8daa66f1964437546376eaa617dd3903bb5f16afc69011a6d8263783813ada3f"},{"ts":"2026-07-17T02:41:55.695Z","model":"owner","action":"voxel_divide","prompt":"","input":"semax-nerve-damage","response":"20 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8daa66f1964437546376eaa617dd3903bb5f16afc69011a6d8263783813ada3f","hash":"df1756db141df0ef9c37f786e48c0d1e103140f0a6f5e587342f1842962e7f86"},{"ts":"2026-08-05T10:15:04.366Z","model":"claude-opus-5","action":"citation-identity-repair","why":"","prompt":"","input":"","response":"","tokens_in":0,"tokens_out":0,"cost":0,"prev":"df1756db141df0ef9c37f786e48c0d1e103140f0a6f5e587342f1842962e7f86","hash":"e5a585dd13655cceaff966a22681831d3cef6af86cd68c47527839671f081b7a"}],"energy":{"passes":3,"tokens_in":16759,"tokens_out":2543,"tokens_total":19302,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1,"claude-opus-5":1},"head":"e5a585dd13655cceaff966a22681831d3cef6af86cd68c47527839671f081b7a"},"posted_at":"2026-06-29T21:33:17.731Z","created_at":"2026-06-29T21:33:17.731Z","updated_at":"2026-08-05T10:15:04.366Z","machine":{"shape":"article.machine/v1","slug":"semax-nerve-damage","kind":"article","read":{"human":"https://miscsubjects.com/a/semax-nerve-damage","json":"https://miscsubjects.com/api/articles/semax-nerve-damage","bundle":"https://miscsubjects.com/api/articles/semax-nerve-damage/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":5,"contributions":1,"revisions":2,"objections_url":"https://miscsubjects.com/api/articles/semax-nerve-damage/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=semax-nerve-damage","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semax-nerve-damage\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semax-nerve-damage\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/semax-nerve-damage/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"semax-nerve-damage\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/semax-nerve-damage | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/semax-nerve-damage","json":"/api/articles/semax-nerve-damage","markdown":"/api/articles/semax-nerve-damage/bundle?format=markdown","skill":"/api/articles/semax-nerve-damage/skill","topology":"/api/articles/semax-nerve-damage/topology","versions":"/api/articles/semax-nerve-damage/revisions","invocations":"/api/articles/semax-nerve-damage/invocations"},"editorial_review":null,"editorial_audit":{"slug":"semax-nerve-damage","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"0c6a2bfccd8824f4c8e25ffa12f4a66b9831edc3d41062962bc8fbec2bde6964","object":{"object_type":"article-object","identity":{"id":"article:semax-nerve-damage","slug":"semax-nerve-damage","title":"Semax for Nerve Damage: Evidence Review"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/semax-nerve-damage","role":"explain","audience":"human"},"skill":{"route":"/api/articles/semax-nerve-damage/skill","role":"direct behavior","audience":"model","content":"---\nname: semax-nerve-damage\ndescription: Apply the Semax for Nerve Damage: Evidence Review article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# Semax for Nerve Damage: Evidence Review\n\nThis Skill is the behavioral expression of [the canonical article](/a/semax-nerve-damage). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/semax-nerve-damage.\n- Read claims and relationships at /api/articles/semax-nerve-damage/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Nerve damage involves degeneration where breakdown of neurons, axons, or myelin outpaces natural repair. Layers include loss of trophic support like BDNF, inflammation after injury, impaired survival signaling during st\n\n## Representations\n\n- Human: /a/semax-nerve-damage\n- JSON: /api/articles/semax-nerve-damage\n- Relationships: /api/articles/semax-nerve-damage/topology\n- History: /api/articles/semax-nerve-damage/revisions\n"},"json":{"route":"/api/articles/semax-nerve-damage","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/semax-nerve-damage/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","semax","nerve","damage"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/semax-nerve-damage/invocations?status=success","failure_events":"/api/articles/semax-nerve-damage/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"semax-nerve-damage","title":"Semax for Nerve Damage: Evidence Review","body":"## What's breaking down\nNerve damage involves degeneration where breakdown of neurons, axons, or myelin outpaces natural repair. Layers include loss of trophic support like BDNF, inflammation after injury, impaired survival signaling during stress or ischemia, and reduced plasticity in affected neural circuits. If your nerve issue stems from these, repair-focused approaches target rebuilding connections rather than only suppressing symptoms.\n\n## Why Semax might help you\n1. What keeps failing: BDNF decline reduces neuron survival and connection building after damage.\n2. What Semax is studied to do: Studied for increasing BDNF expression and supporting neural repair pathways in models of injury.\n3. Therefore for you: If BDNF or related neural support is part of your problem, Semax is discussed because it targets repair at the molecular level — not because it masks pain or reduces load.\n\n## How these fit together\nSingle-compound focus. Semax maps to the neural repair layer. If your profile includes other factors, additional compounds would address separate layers such as inflammation or mechanical stress.\n\n## What the evidence actually shows\nHuman data come from Russian studies on ischemic stroke recovery and glaucomatous optic neuropathy. One study found Semax improved functional recovery and motor performance in stroke patients (preclinical and human stroke data, mechanistic via gene expression). Another examined Semax in glaucoma patients with normalized eye pressure and noted neuroprotective effects (human, small scale).\n\nPreclinical data: Multiple rat studies show Semax increases BDNF mRNA and protein in hippocampus and cortex after ischemia or stress, enhances neuron survival under hypoxia or glutamate toxicity, and reduces infarct size in photothrombosis models (preclinical).\n\nNo large Western human trials specifically for peripheral nerve damage or general neuropathy.\n\n## What scientists say\nResearchers note Semax's neuroprotective properties in ischemia models and links to BDNF/trkB signaling for plasticity (mechanistic from cell and animal work). They emphasize rapid gene expression changes but call for more translation data.\n\n## What people say on Reddit\nAnecdotes are limited; discussions more often cover other peptides like ARA-290 for neuropathic pain or BPC-157 for various injuries. Rare mentions tie Semax to cognitive or mood support rather than direct nerve repair (anecdotal).\n\n## What people say on X\nLimited public posts; occasional references to Russian clinical use for stroke or cognitive issues, with no widespread reports on peripheral nerve damage outcomes (anecdotal).\n\n## What we do not know\nDirect human evidence for Semax in peripheral nerve damage or neuropathy is absent. Long-term outcomes beyond acute stroke settings remain unstudied in published Western literature. Translation from rat BDNF changes to human nerve regeneration is unproven.\n\n## Safety and limits\nSemax appears well-tolerated in studied contexts with no major adverse signals reported in available stroke and animal work. Data gaps mean individual responses vary; consult sources for full context. Evidence inventory: ~4-6 human studies (mostly Russian stroke/optic), 10+ rat/molecular studies, minimal anecdotes.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/semax-nerve-damage/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Semax improved functional recovery and motor performance in ischemic stroke patients in Russian clinical studies.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Provides the main human data point for neural injury recovery.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:07:55.903Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Rat studies show Semax increases BDNF mRNA and protein levels in hippocampus and cortex after ischemia.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2","s3"],"source_status":"sourced","why_material":"Core mechanistic evidence for repair pathway.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:07:55.903Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Semax showed neuroprotective effects in small human studies of glaucomatous optic neuropathy.","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Extends human data to optic nerve damage.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:07:55.903Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No large-scale Western human trials exist for Semax in peripheral nerve damage.","section":"What we do not know","tier":"mechanistic","source_ids":["s5"],"source_status":"sourced","why_material":"Highlights evidence gap for the specific condition.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:07:55.903Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/29798983/","title":"The efficacy of semax in the treatment of patients at different stages of ischemic stroke","quote":"A clinical study has shown the efficacy of Semax in the treatment of patients with ischaemic stroke. The peptide improves functional recovery and motor performance.","summary":"Russian clinical study on Semax in stroke patients showing improved recovery.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:07:55.565Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"e3fe76275aacc322815f6fa17330583550888708389d8d86a0bfb67822328563"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/16996037/","title":"Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus","quote":"a single application of Semax results in a maximal 1.4-fold increase of BDNF protein levels","summary":"Identifier corrected 2026-08-05: it read PMID 17045981, which is \"Monitoring micronutrients in cigarette smokers\". Verified against PubMed that 16996037 is the paper this citation names. Rat study demonstrating BDNF upregulation by Semax.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:07:55.565Z","link_status":"ok","quote_status":"unverified","prev":"e3fe76275aacc322815f6fa17330583550888708389d8d86a0bfb67822328563","hash":"4251e23c2cacd5f28b52a713400f77222845016a78837e203c37f02123f1bbfe","pmid":"16996037","external_id":"16996037"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/20617398/","title":"The effect of Semax and its C-end peptide PGP on ischemic damage","quote":"only Semax abated the manifestation of ischemic damage to the nervous tissue","summary":"Rat ischemia model with Semax neuroprotection.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:07:55.565Z","link_status":"ok","quote_status":"verified","prev":"4251e23c2cacd5f28b52a713400f77222845016a78837e203c37f02123f1bbfe","hash":"22e9585e3439ef5589e339ee6f0af9dca5c5813e8aeea3dd28f5b6de4c1e0eb4"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/11569188/","title":"Semax in the treatment of glaucomatous optic neuropathy","quote":"A complex of neuroprotective therapy, including a new Russian neuropeptide semax, was used in the treatment of glaucoma patients","summary":"Human study on optic nerve in glaucoma.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:07:55.565Z","link_status":"ok","quote_status":"verified","prev":"22e9585e3439ef5589e339ee6f0af9dca5c5813e8aeea3dd28f5b6de4c1e0eb4","hash":"d2f2f43408483ecc83a378e8c9594a7a243d3d08d78c019ff21df62020fb119e"},{"id":"s5","type":"other","url":"https://saraszalmd.substack.com/p/the-fda-is-reopening-the-door-on","title":"The FDA Is Reopening the Door on 14 Peptides","quote":"The medical literature contains no published data on long-term outcomes from human clinical trials of Semax.","summary":"Notes lack of extensive long-term human data.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:07:55.565Z","link_status":"ok","quote_status":"unverified","prev":"d2f2f43408483ecc83a378e8c9594a7a243d3d08d78c019ff21df62020fb119e","hash":"554d1130e1fb68c35d81712c496a0486c6dc61589d84d3136016d34b6a4c0e97"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":2,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T00:07:56.284Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Semax for Nerve Damage: Evidence Review","register":"source_ledger","body":"## What's breaking down\nNerve damage involves degeneration where breakdown of neurons, axons, or myelin outpaces natural repair. Layers include loss of trophic support like BDNF, inflammation after injury, impaired survival signaling during stress or ischemia, and reduced plasticity in affected neural circuits. If your nerve issue stems from these, repair-focused approaches target rebuilding connections rather than only suppressing symptoms.\n\n## Why Semax might help you\n1. What keeps failing: BDNF decline reduces neuron survival and connection building after damage.\n2. What Semax is studied to do: Studied for increasing BDNF expression and supporting neural repair pathways in models of injury.\n3. Therefore for you: If BDNF or related neural support is part of your problem, Semax is discussed because it targets repair at the molecular level — not because it masks pain or reduces load.\n\n## How these fit together\nSingle-compound focus. Semax maps to the neural repair layer. If your profile includes other factors, additional compounds would address separate layers such as inflammation or mechanical stress.\n\n## What the evidence actually shows\nHuman data come from Russian studies on ischemic stroke recovery and glaucomatous optic neuropathy. One study found Semax improved functional recovery and motor performance in stroke patients (preclinical and human stroke data, mechanistic via gene expression). Another examined Semax in glaucoma patients with normalized eye pressure and noted neuroprotective effects (human, small scale).\n\nPreclinical data: Multiple rat studies show Semax increases BDNF mRNA and protein in hippocampus and cortex after ischemia or stress, enhances neuron survival under hypoxia or glutamate toxicity, and reduces infarct size in photothrombosis models (preclinical).\n\nNo large Western human trials specifically for peripheral nerve damage or general neuropathy.\n\n## What scientists say\nResearchers note Semax's neuroprotective properties in ischemia models and links to BDNF/trkB signaling for plasticity (mechanistic from cell and animal work). They emphasize rapid gene expression changes but call for more translation data.\n\n## What people say on Reddit\nAnecdotes are limited; discussions more often cover other peptides like ARA-290 for neuropathic pain or BPC-157 for various injuries. Rare mentions tie Semax to cognitive or mood support rather than direct nerve repair (anecdotal).\n\n## What people say on X\nLimited public posts; occasional references to Russian clinical use for stroke or cognitive issues, with no widespread reports on peripheral nerve damage outcomes (anecdotal).\n\n## What we do not know\nDirect human evidence for Semax in peripheral nerve damage or neuropathy is absent. Long-term outcomes beyond acute stroke settings remain unstudied in published Western literature. Translation from rat BDNF changes to human nerve regeneration is unproven.\n\n## Safety and limits\nSemax appears well-tolerated in studied contexts with no major adverse signals reported in available stroke and animal work. Data gaps mean individual responses vary; consult sources for full context. Evidence inventory: ~4-6 human studies (mostly Russian stroke/optic), 10+ rat/molecular studies, minimal anecdotes.","claims":[{"id":"c1","text":"Semax improved functional recovery and motor performance in ischemic stroke patients in Russian clinical studies.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Provides the main human data point for neural injury recovery.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:07:55.903Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Rat studies show Semax increases BDNF mRNA and protein levels in hippocampus and cortex after ischemia.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2","s3"],"source_status":"sourced","why_material":"Core mechanistic evidence for repair pathway.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:07:55.903Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Semax showed neuroprotective effects in small human studies of glaucomatous optic neuropathy.","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Extends human data to optic nerve damage.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:07:55.903Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No large-scale Western human trials exist for Semax in peripheral nerve damage.","section":"What we do not know","tier":"mechanistic","source_ids":["s5"],"source_status":"sourced","why_material":"Highlights evidence gap for the specific condition.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:07:55.903Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/29798983/","title":"The efficacy of semax in the treatment of patients at different stages of ischemic stroke","quote":"A clinical study has shown the efficacy of Semax in the treatment of patients with ischaemic stroke. The peptide improves functional recovery and motor performance.","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/17045981/","title":"Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus","quote":"a single application of Semax results in a maximal 1.4-fold increase of BDNF protein levels","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/20617398/","title":"The effect of Semax and its C-end peptide PGP on ischemic damage","quote":"only Semax abated the manifestation of ischemic damage to the nervous tissue","link_status":"ok","quote_status":"verified"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/11569188/","title":"Semax in the treatment of glaucomatous optic neuropathy","quote":"A complex of neuroprotective therapy, including a new Russian neuropeptide semax, was used in the treatment of glaucoma patients","link_status":"ok","quote_status":"verified"},{"id":"s5","type":"other","url":"https://saraszalmd.substack.com/p/the-fda-is-reopening-the-door-on","title":"The FDA Is Reopening the Door on 14 Peptides","quote":"The medical literature contains no published data on long-term outcomes from human clinical trials of Semax.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":16759,"tokens_out":2543,"cost":0.02730625,"prev_hash":"genesis","hash":"242b34f65688e634d656210aaf63f2ae7584535b91df40d3b5d0579164f94734"}],"provenance":[{"ts":"2026-06-30T00:07:56.284Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Semax for Nerve Damage\nSlug: semax-nerve-damage\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"semax\",\"name\":\"Semax\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"semax\",\"name\":\"Semax\",\"section_title\":\"Why Semax might help you\",\"layer\":\"neural / cognitive\",\"steps\":[\"**What keeps failing:** BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\",\"**What Semax is studied to do:** Studied for BDNF and neural support — building connections, not sedating symptoms.\",\"**Therefore for you:** If that layer is part of your problem, Semax is discussed because it targets repair (neural / cognitive) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\\n2. **What Semax is studied to do:** Studied for BDNF and neural support — building connections, not sedating symptoms.\\n3. **Therefore for you:** If that layer is part of your problem, Semax is discussed because it targets repair (neural / cognitive) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target othe","response":"{\n  \"slug\": \"semax-nerve-damage\",\n  \"title\": \"Semax for Nerve Damage: Evidence Review\",\n  \"body\": \"## What's breaking down\\nNerve damage involves degeneration where breakdown of neurons, axons, or myelin outpaces natural repair. Layers include loss of trophic support like BDNF, inflammation after injury, impaired survival signaling during stress or ischemia, and reduced plasticity in affected neural circuits. If your nerve issue stems from these, repair-focused approaches target rebuilding connections rather than only suppressing symptoms.\\n\\n## Why Semax might help you\\n1. What keeps failing: BDNF decline reduces neuron survival and connection building after damage.\\n2. What Semax is studied to do: Studied for increasing BDNF expression and supporting neural repair pathways in models of injury.\\n3. Therefore for you: If BDNF or related neural support is part of your problem, Semax is discussed because it targets repair at the molecular level — not because it masks pain or reduces load.\\n\\n## How these fit together\\nSingle-compound focus. Semax maps to the neural repair layer. If your profile includes other factors, additional compounds would address separate layers such as inflammation or mechanical stress.\\n\\n## What the evidence actually shows\\nHuman data come from Russian studies on ischemic stroke recovery and glaucomatous optic neuropathy. One study found Semax improved functional recovery and motor performance in stroke patients (preclinical and human stroke data, mechanistic via gene expression). Another examined Semax in glaucoma patients with normalized eye pressure and noted neuroprotective effects (human, small scale).\\n\\nPreclinical data: Multiple rat studies show Semax increases BDNF mRNA and protein in hippocampus and cortex after ischemia or stress, enhances neuron survival under hypoxia or glutamate toxicity, and reduces infarct size in photothrombosis models (preclinical).\\n\\nNo large Western human trials specifically for peripheral nerve damage or","tokens_in":16759,"tokens_out":2543,"cost":0,"prev":"genesis","hash":"8daa66f1964437546376eaa617dd3903bb5f16afc69011a6d8263783813ada3f"},{"ts":"2026-07-17T02:41:55.695Z","model":"owner","action":"voxel_divide","prompt":"","input":"semax-nerve-damage","response":"20 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8daa66f1964437546376eaa617dd3903bb5f16afc69011a6d8263783813ada3f","hash":"df1756db141df0ef9c37f786e48c0d1e103140f0a6f5e587342f1842962e7f86"},{"ts":"2026-08-05T10:15:04.366Z","model":"claude-opus-5","action":"citation-identity-repair","why":"","prompt":"","input":"","response":"","tokens_in":0,"tokens_out":0,"cost":0,"prev":"df1756db141df0ef9c37f786e48c0d1e103140f0a6f5e587342f1842962e7f86","hash":"e5a585dd13655cceaff966a22681831d3cef6af86cd68c47527839671f081b7a"}],"energy":{"passes":3,"tokens_in":16759,"tokens_out":2543,"tokens_total":19302,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1,"claude-opus-5":1},"head":"e5a585dd13655cceaff966a22681831d3cef6af86cd68c47527839671f081b7a"},"posted_at":"2026-06-29T21:33:17.731Z","created_at":"2026-06-29T21:33:17.731Z","updated_at":"2026-08-05T10:15:04.366Z","machine":{"shape":"article.machine/v1","slug":"semax-nerve-damage","kind":"article","read":{"human":"https://miscsubjects.com/a/semax-nerve-damage","json":"https://miscsubjects.com/api/articles/semax-nerve-damage","bundle":"https://miscsubjects.com/api/articles/semax-nerve-damage/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":5,"contributions":1,"revisions":2,"objections_url":"https://miscsubjects.com/api/articles/semax-nerve-damage/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=semax-nerve-damage","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semax-nerve-damage\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semax-nerve-damage\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/semax-nerve-damage/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"semax-nerve-damage\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/semax-nerve-damage | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/semax-nerve-damage","json":"/api/articles/semax-nerve-damage","markdown":"/api/articles/semax-nerve-damage/bundle?format=markdown","skill":"/api/articles/semax-nerve-damage/skill","topology":"/api/articles/semax-nerve-damage/topology","versions":"/api/articles/semax-nerve-damage/revisions","invocations":"/api/articles/semax-nerve-damage/invocations"},"editorial_review":null,"editorial_audit":{"slug":"semax-nerve-damage","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"0c6a2bfccd8824f4c8e25ffa12f4a66b9831edc3d41062962bc8fbec2bde6964"}}}